


Regio- and Stereocontrolled Access to γ -Boronated Unsaturated Amino Esters and Derivatives from (Z)-Alkenyl 1,2-Bis(boronates)

Tailor Sridhar,^{†,‡} Fabienne Berrée,[†] Gangavaram V. M. Sharma,^{*,‡} and Bertrand Carboni^{*,†}

[†]Institut des Sciences Chimiques de Rennes, UMR 6226 CNRS–Université de Rennes 1, 263 Avenue du Général Leclerc, Campus de Beaulieu, Bâtiment 10A, 35042 Rennes Cedex, France

[‡]Organic and Biomolecular Chemistry Division, CSIR–Indian Institute of Chemical Technology, Tarnaka, Hyderabad 500 607, India

S Supporting Information




ABSTRACT: The Borono–Mannich reaction of (Z)-1-alkene-1,2-diboronic esters proceeded regioselectively at the terminal C–B bond to afford (E)- γ -boronated unsaturated amino esters in good yields. These compounds were then subjected to Suzuki couplings for the creation of diversely substituted olefinic amino acid systems. Several other functional transformations were also carried out to illustrate the synthetic utility of the Petasis products.

Alkenyl boronates constitute an important family of organoboron compounds whose utility in organic synthesis has been repeatedly illustrated.¹ Among this class of versatile intermediates, 1-alkene-1,2-diboronic esters **1** have been relatively poorly studied. Since the discovery of an efficient *cis*-selective route to these species by platinum-catalyzed diboration of alkynes in 1993, most of the work related to these compounds has been focused on their metal-catalyzed cross-coupling reactions.² Regioselective palladium Suzuki coupling at the terminal C–B bond can be followed by the introduction of a second aryl or heteroaryl moiety to afford unsymmetrical tetrasubstituted alkenes (Scheme 1).^{3,4} By contrast, the use of a differently protected diboron, instead of the classical bis-(pinacolato)diboron, allowed internal selective cross coupling.⁵ Other convincing examples of the interest of compounds **1** were provided by couplings with 2 equiv of the same electrophile^{2a,3e,6} and annulation reactions with aromatic dihalides.⁷ Much less has been reported about other aspects of their reactivity. Double carbomethoxylation,⁸ enantioselective hydrogenation,⁹ fluoro-deboronation,¹⁰ and Diels–Alder cycloaddition¹¹ were recently described (Scheme 1), whereas, to the best of our knowledge, no Borono–Mannich reactions have been hitherto carried out with the 1,2-diboronic esters as substrates.

This transformation, now referred to as the Petasis reaction, involving aldehyde or ketone, unsaturated organoborane, and amine partners, enables the preparation of a wide variety of molecules with high levels of structural diversity.^{12,13} In the course of our research programs devoted to the synthesis of amino acids¹⁴ and multicomponent assembly processes involving boronic acids or their derivatives,¹⁵ in this article, we have investigated a new route to γ -boronated unsaturated amino esters **2** from bis(boronates) **1** (Scheme 2). These compounds may have interesting biological properties, by themselves or by their derivatives;¹⁶ the presence of a boronate group also allows access

Scheme 1. Some Representative Examples of the Reactivity of 1-Alkene-1,2-diboronic Esters **1**




through diverse functionalizations, for example, cross coupling, oxidation, or azidation,¹ to a number of diversely substituted amino acids or heterocycles.

Received: October 8, 2013

Published: December 5, 2013

Scheme 2. Access to Diversely Substituted Amino Esters from 1,2-Bis Boronates



(*Z*)-Alkenyl 1,2-bis(boronates) **1** were prepared in good yields according to a known protocol² from the corresponding alkynes, 1-hexyne, 3-hexyne, propargyl trimethylsilane, and phenylacetylene, independently on reaction with bis(pinacolato)-diboron in the presence of tetrakis(triphenylphosphine)-platinum as catalyst in DMF/toluene at 80 °C for 18 h. These boronic esters **1a–d** were then subjected to regioselective Petasis reaction at the terminal C–B bond using different amines and glyoxylic acid in HFIP (1,1,1,3,3,3-hexafluoropropan-2-ol) at room temperature for 8 h to give the corresponding γ -boronated unsaturated amino acids. Poor results were obtained with other solvents, such as methanol or THF, as previously reported,¹⁷ which was attributed to the positive effect of HFIP on the formation of ionic intermediates and stabilization of polarized transition states. Thus, prepared amino acids were directly subjected to esterification with an ethereal solution of CH₂N₂ to afford corresponding γ -boronated esters **2** with diversity (Table 1). A single isomer was present with an *E* stereochemistry, as evidenced from NOESY experiments; no product resulting from a double Petasis condensation was detected under these experimental conditions. Yields are moderate to good (50–69% over two steps), with the best results being generally obtained with morpholine or *N*-substituted piperazines (entries 1, 3, 4, and 7). The reaction also took place with (*S*)-(-)-*N*-benzyl- α -methylbenzylamine, a more sterically demanding amine than dibenzylamine, but with poor diastereoselectivity (dr 58:42) (entry 5). In addition, it should also be noted that no reaction occurred at room temperature with the primary amine, PhCH₂NH₂, and **1a** (entry 6) as with the tetrasubstituted bisboronate **1d** and morpholine (entry 11), whereas complex, inseparable mixtures are produced upon heating at 50 °C in HFIP for 2 h.

The thus obtained esters **2** were engaged in Suzuki–Miyaura cross-coupling reactions with different aromatic halides in the presence of [1,1'-bis(diphenylphosphino)ferrocene]-dichloropalladium(II) and potassium phosphate tribasic monohydrate in THF/H₂O at reflux.¹⁸ The corresponding esters **3** were obtained in good (60–89%) yields (Table 2), with no significant influence being noticed on the basis of the nature of the aromatic ring substituent (entries 5 and 6, 8 and 9). Heteroaromatic halide can be used with similar efficiency (entry 3). The coupling reactions proceeded with retention of configuration to afford the *Z* isomers as single products except in the case of 2-bromo toluene, which gave a 58:42 mixture of geometrical isomers.

The synthetic utility of the amino esters **2** was also demonstrated by several transformations of the boronic ester group (Scheme 3). For example, oxidation of **2a** with sodium

perborate in THF/water afforded γ -oxo α -aminoester **4** in 74% yield, whereas the copper-catalyzed reaction with sodium azide in methanol gave alkenylazide **5**.¹⁹ In addition, a one-pot procedure, which avoided the need to isolate this potentially unstable species, was employed to synthesize 4-aryl-1,2,3-triazole **6** directly from **2a** and phenylacetylene in an overall yield of 36%.^{19,20}

In conclusion, a regioselective Petasis reaction has been performed for the first time at the terminal C–B bond of (*Z*)-1-alkene-1,2-diboronic esters. The resulting amino esters were then subjected to Suzuki coupling with the second boronate moiety to give the corresponding amino esters. This protocol provides an opportunity not only for the conversion of bisboronates into Petasis/Suzuki products but also to other functionalized amino esters derivatives by exploiting the versatility of the boronic ester group.

EXPERIMENTAL SECTION


General Information and Materials. All commercially available chemicals were used without further purification. Tetrahydrofuran (THF), diethylether, and 1,1,1,3,3,3-hexafluoropropan-2-ol (HFIP) were used as received. Analytical thin-layer chromatography was performed on silica gel 60 F254 plates. The compounds were characterized by ¹H, ¹³C, and ¹¹B NMR techniques. ¹H and ¹³C spectra were recorded in CDCl₃ (internal standard: 7.26 ppm, ¹H; 77.00 ppm, ¹³C) and ¹¹B NMR chemical shifts to external BF₃·OEt₂ (0.0 ppm). High-resolution mass spectra (HMRS) were recorded on a micro-TOF-Q II mass analyzer or Q-TOF 2 using positive ion electrospray. Compounds **1a**,¹⁰ **1b**,^{3d} **1c**,^{2b} and **1d**^{3b} were prepared according to a known protocol.² The ethereal solution of CH₂N₂ was generated from *N*-nitroso-*N*-methylurea according to the literature.²¹

General Procedure for Petasis Reaction. Glyoxylic acid monohydrate (0.33 mmol) and amine (0.33 mmol) were added to a stirred solution of bispinacolate ester **1** (0.3 mmol) in hexafluoropropan-2-ol (2 mL) under an argon atmosphere at room temperature. The reaction mixture was stirred for 8 h. The solvent was removed under reduced pressure to give a residue that was directly used for the further esterification reaction. To a solution of the crude acid in diethylether (5 mL) at 0 °C was added a solution of CH₂N₂ in ether²¹ until the persistence of yellow color. After 2 h, the solvent was evaporated, and the resulting residue was purified by column chromatography (230–400 mesh silica gel, EtOAc in cyclohexane) to afford γ -boronated unsaturated amino esters **2** in 50–69% yield (over two steps) (Table 1).

Methyl 4-(4,4,4,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(morpholino)-oct-3-enoate 2a. Seventy six milligrams (69%). Colorless oil, *R*_f = 0.25 (EtOAc/cyclohexane 20:80). ¹H NMR (300 MHz, CDCl₃): δ 5.96 (d, *J* = 9.8 Hz, 1H), 4.32 (d, *J* = 9.8 Hz, 1H), 3.73 (t, *J* = 4.3 Hz, 4H), 3.69 (s, 3H), 2.59–2.48 (m, 4H), 2.24–2.07 (m, 2H), 1.41–1.21 (m, 4H), 1.27 (s, 12H), 0.86 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 171.8, 140.4 (br), 136.7, 83.4, 69.1, 66.7, 51.9, 51.0, 36.4, 31.7, 24.8, 24.7, 22.2, 13.9. ¹¹B NMR (96 MHz, CDCl₃): δ 30.0 (br s). HRMS (ESI+): *m/z* (M + H)⁺ calcd for C₁₉H₃₅NO₅¹¹B, 368.26083; found, 368.2608.

Methyl 2-Dibenzylamino-4-(4,4,4,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-oct-3-enoate 2b. Seventy two milligrams (50%). Colorless oil, *R*_f = 0.40 (EtOAc/cyclohexane 30:70). ¹H NMR (300 MHz, CDCl₃): δ 7.39–7.40 (m, 4H), 7.29–7.26 (m, 4H), 7.20–7.19 (m, 2H), 6.16 (d, *J* = 9.3 Hz, 1H), 4.74 (d, *J* = 9.3 Hz, 1H), 3.76 (s, 4H), 3.69 (s, 3H), 2.26–2.11 (m, 2H), 1.42–1.29 (m, 4H), 1.09 (s, 6H), 1.05 (s, 6H), 0.91 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 173.2, 139.8, 137.7, 128.7, 128.0, 126.6, 83.0, 63.2, 54.9, 51.4, 36.5, 31.9, 26.9, 24.6, 24.4, 22.3, 14.0 (C α to boron not visible). ¹¹B NMR (96 MHz, CDCl₃): δ 30.4 (br s). HRMS (ESI+): *m/z* (M + H)⁺ calcd for C₂₉H₄₁NO₄¹¹B, 478.31286; found, 478.3129.

Methyl 4-(4,4,4,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(pyridin-4-yl)piperazino-oct-3-enoate 2c. Seventy six milligrams (57%). Colorless oil, *R*_f = 0.30 (EtOAc/cyclohexane 30:70). ¹H NMR (300 MHz, CDCl₃): δ 8.18 (d, *J* = 3.9 Hz, 1H), 7.46 (t, *J* = 7.4 Hz, 1H), 6.64–

Table 1. Borono–Mannich Route to γ -Boronated Unsaturated Amino Esters 2


entry	R	R'	amine	product	yield (%) ^a
1	<i>n</i> -Bu	H			69
2	<i>n</i> -Bu	H			50
3	<i>n</i> -Bu	H			57
4	<i>n</i> -Bu	H			63
5	<i>n</i> -Bu	H			58 ^b
6	<i>n</i> -Bu	H	H ₂ N-CH ₂ Ph		nr
7	TMSCH ₂	H			60
8	TMSCH ₂	H			53
9	Ph	H			53
10	Ph	H			54
11	Et	Et			nr










^aYields are calculated over two steps after purification by column chromatography. ^bMixtures of two diastereomers (58:42).

6.59 (m, 2H), 5.99 (d, *J* = 9.8 Hz, 1H), 4.40 (d, *J* = 9.8 Hz, 1H), 3.72 (s, 3H), 3.57 (t, *J* = 4.9 Hz, 4H), 2.66–2.53 (m, 4H), 2.18–2.02 (m, 2H), 1.41–1.26 (m, 4H), 1.26 (s, 12H), 0.87 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 172.2, 147.8, 137.5, 137.2, 113.2, 107.0, 83.4, 68.9, 51.9, 50.4, 45.1, 36.5, 31.8, 24.8, 24.7, 22.3, 13.9. ¹¹B NMR (96 MHz,

CDCl₃): δ 29.8 (br s). HRMS (ESI⁺): *m/z* (M + H)⁺ calcd for C₂₄H₃₉N₃O₄¹¹B, 444.30336; found, 444.3037.

Methyl 4-(4,4,4,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-2-[4-(1,1-dimethylethoxy)carbonyl]piperazino-oct-3-enoate 2d. Eighty eight milligrams (63%). Colorless oil, *R*_f = 0.30 (EtOAc/cyclohexane 30:70).

Table 2. Suzuki Couplings with γ -Boronated Unsaturated Amino Esters 2


entry	boronate	Ar	product	yield (%) ^a
1	2a	4-MeC ₆ H ₄		75
2	2a	2-MeC ₆ H ₄		60
3	2a	3-Pyr		82
4	2b	4-MeC ₆ H ₄		86
5	2c	4-NO ₂ C ₆ H ₄		82
6	2d	4-MeOC ₆ H ₄		89
7	2g	4-MeOC ₆ H ₄		80
8	2i	4-MeC ₆ H ₄		80
9	2j	4-NO ₂ C ₆ H ₄		78

^aYields are calculated after purification by column chromatography.

¹H NMR (300 MHz, CDCl₃): δ 5.90 (d, J = 9.7 Hz, 1H), 4.29 (d, J = 9.7 Hz, 1H), 3.65 (s, 3H), 3.41–3.39 (m, 4H), 2.56–2.40 (m, 4H), 2.23–2.07 (m, 2H), 1.40 (s, 9H), 1.34–1.22 (m, 4H), 1.22 (s, 12H), 0.93 (t, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 172.0, 154.6, 139.8 (br), 137.1, 83.3, 79.4, 68.5, 51.7, 50.2, 43.0 (br), 36.4, 31.7, 28.3, 24.7, 24.6, 22.2, 13.8. ¹¹B NMR (96 MHz, CDCl₃): δ 30.2 (br s). HRMS (ESI⁺): m/z (M + Na)⁺ calcd for C₂₄H₄₃N₂O₆¹¹BNa, 489.31119; found, 489.3112.

Methyl 2-(S)-Benzyl- α -methylbenzylamino-4-(4,4,4,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-oct-3-enoate 2e. Eighty five milligrams

(58%). Colorless oil, R_f = 0.29 (EtOAc/cyclohexane 8:92). Mixture of 2 diastereomers (55:45). ¹H NMR (400 MHz, CDCl₃): δ 7.45–7.43 (m, 3H), 7.36–7.15 (m, 7H), 6.16 (d, J = 9.3 Hz, 0.55H), 6.00 (d, J = 9.1 Hz, 0.45H), 4.93 (d, J = 9.2 Hz, 0.45H), 4.86 (d, J = 9.4 Hz, 0.55H), 4.12–4.06 (m, 1H), 3.98 (d, J = 15.2 Hz, 0.55H), 3.93 (d, J = 15.4 Hz, 0.55H), 3.89 (d, J = 15.4 Hz, 0.45H), 3.81 (d, J = 15.2 Hz, 0.45H), 3.65 (s, 3 \times 0.45H), 3.47 (s, 3 \times 0.55H), 2.20–2.04 (m, 2H), 1.40 (d, J = 7.2 Hz, 3 \times 0.45H), 1.38 (d, J = 7.4 Hz, 3 \times 0.55H), 1.34–1.25 (m, 4H), 1.19 (s, 12 \times 0.45H), 1.16 (s, 12 \times 0.55H), 0.89 (t, J = 7.1 Hz, 3 \times 0.45H), 0.88 (t, J = 7.0 Hz, 3 \times 0.55H). ¹³C NMR (100 MHz, CDCl₃): δ 174.1, 173.6, 144.35, 143.8, 141.9, 141.7, 139.7, 139.2, 136.6 (br), 128.2, 128.1, 127.95, 127.9, 127.85, 127.8, 126.55, 126.5, 126.3, 126.1, 83.0, 83.0, 62.8, 62.5, 59.0, 58.35, 51.7, 51.6, 51.4, 51.2, 36.4, 36.2, 31.8, 31.6, 24.7, 24.5, 24.4, 22.3, 22.2, 16.9, 14.0. ¹¹B NMR (96 MHz, CDCl₃): δ 30.0 (br s). HRMS (ESI⁺): m/z (M + H)⁺ calcd for C₃₀H₄₃NO₄¹¹B, 492.3285; found, 492.3279.

Methyl 4-(4,4,4,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(morpholino)-5-(trimethylsilyl)-pent-3-enoate 2g. Seventy one milligrams (60%). Colorless oil, R_f = 0.25 (EtOAc/cyclohexane 10:90). ¹H NMR (300 MHz, CDCl₃): δ 5.80 (d, J = 9.9 Hz, 1H), 4.47 (d, J = 9.9 Hz, 1H), 3.74 (t, J = 4.0 Hz, 4H), 3.68 (s, 3H), 2.60–2.46 (m, 4H), 1.67 (s, 2H), 1.25 (s, 6H), 1.24 (s, 6H), –0.05 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 171.9, 137.2 (br), 135.1, 83.5, 69.0, 66.7, 51.8, 51.0, 26.6, 24.9, –1.5. ¹¹B NMR (96 MHz, CDCl₃): δ 29.7 (br s). HRMS (ESI⁺): m/z (M + Na)⁺ calcd for C₁₉H₃₆NO₅¹¹BNaSi, 420.23535; found, 420.2351.


Methyl 2-Benzyl(methyl)amino-4-(4,4,4,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-(trimethylsilyl)-pent-3-enoate 2h. Sixty nine milligrams (53%). Colorless oil, R_f = 0.15 (EtOAc/cyclohexane 3:97). ¹H NMR (400 MHz, CDCl₃): δ 7.40–7.19 (m, 5H), 5.97 (d, J = 9.6 Hz, 1H), 4.73 (d, J = 9.6 Hz, 1H), 3.76–3.54 (m, 2H), 3.73 (s, 3H), 2.21 (s, 3H), 1.73 (s, 2H), 1.23 (s, 6H), 1.21 (s, 6H), 0.00 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 173.1, 139.2 (br), 136.1, 129.2, 128.1, 126.9, 83.3, 67.0, 58.5, 51.6, 38.7, 26.6, 24.9, 24.8, –1.5 (C α to boron not visible). ¹¹B NMR (96 MHz, CDCl₃): δ 29.6 (br s). HRMS (ESI⁺): m/z (M + H)⁺ calcd for C₂₃H₃₉¹¹BNO₄Si, 432.27414; found, 432.2738.

Methyl 4-(4,4,4,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(morpholino)-4-phenyl-but-3-enoate 2i. Sixty two milligrams (53%). Colorless oil, R_f = 0.30 (EtOAc/cyclohexane 20:80). ¹H NMR (400 MHz, CDCl₃): δ 7.42–7.22 (m, 5H), 6.40 (d, J = 9.9 Hz, 1H), 4.32 (d, J = 9.9 Hz, 1H), 3.78–3.74 (m, 4H), 3.74 (s, 3H), 2.67–2.54 (m, 4H), 1.35 (s, 6H), 1.34 (s, 6H). ¹³C NMR (75 MHz, CDCl₃): δ 171.3, 141.3, 138.2, 128.7, 128.3, 127.3, 126.6, 84.1, 70.0, 66.8, 52.1, 51.3, 24.9, 24.7. ¹¹B NMR (96 MHz, CDCl₃): δ 30.3 (br s). HRMS (ESI⁺): m/z (M + Na)⁺ calcd for C₂₁H₃₀¹¹BNO₅Na, 410.21147; found, 410.2112.

Methyl 2-Dibenzylamino-4-(4,4,4,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4-phenyl-but-3-enoate 2j. Eighty one milligrams (54%). Colorless oil, R_f = 0.15 (EtOAc/cyclohexane 3:97). ¹H NMR (400 MHz, CDCl₃): δ 7.39 (d, J = 7.8 Hz, 4H), 7.33–7.24 (m, 8H), 7.21–7.15 (m, 3H), 6.53 (d, J = 9.3 Hz, 1H), 4.73 (d, J = 9.5 Hz, 1H), 3.81 (s, 4H), 3.69 (s, 3H), 1.09 (s, 6H), 1.06 (s, 6H). ¹³C NMR (75 MHz, CDCl₃): δ 172.4, 142.2, 139.9, 139.5, 137.1 (br), 128.7, 128.15, 128.10, 127.4, 126.8, 126.7, 83.7, 63.7, 55.0, 51.6, 24.6, 24.5. ¹¹B NMR (96 MHz, CDCl₃): δ 30.3 (br s). HRMS (ESI⁺): m/z (M + H)⁺ calcd for C₃₁H₃₇NO₄¹¹B, 498.28156; found, 498.2809.

General Procedure for Suzuki Coupling. To a solution of ester 2 (0.14 mmol) in THF (1.2 mL) and water (30 μ L) under an argon atmosphere were added [1,1'-bis (diphenyl phosphino)ferrocene]-dichloropalladium(II) (0.0028 mmol), potassium phosphate tribasic monohydrate (0.42 mmol), and arylbromide (0.28 mmol) at room temperature. The reaction mixture was heated at reflux for 8 h, cooled to room temperature, and diluted with water. The aqueous layer was extracted with Et₂O (2 \times 15 mL). The combined organic extracts were dried over MgSO₄ and evaporated under vacuum. The residue was purified by column chromatography (230–400 mesh silica gel, EtOAc in cyclohexane) to give ester 3 in 69–89% yield (Table 2).

Methyl 4-(4-Methylphenyl)-2-(morpholino)-oct-3-enoate 3a. Thirty five milligrams (75%). Colorless oil, R_f = 0.40 (EtOAc/cyclohexane 10:90). ¹H NMR (300 MHz, CDCl₃): δ 7.14 (d, J = 7.9 Hz, 2H), 7.02 (d, J = 7.9 Hz, 2H), 5.48 (d, J = 9.9 Hz, 1H), 3.73 (s, 3H), 3.69 (t, J = 4.5 Hz, 4H), 3.52 (d, J = 9.9 Hz, 1H), 2.58–2.45 (m, 2H),

Scheme 3. Synthetic Transformations of γ -Boronated Unsaturated Amino Ester 2a

2.38–2.26 (m, 4H), 2.36 (s, 3H), 1.33–1.22 (m, 4H), 0.84 (t, $J = 7.0$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 171.8, 149.3, 136.9, 136.8, 128.9, 128.0, 120.0, 67.9, 66.7, 52.0, 50.9, 39.4, 29.8, 22.2, 21.2, 13.8. HRMS (ESI⁺): m/z ($M + \text{Na}$)⁺ calcd for $\text{C}_{20}\text{H}_{29}\text{NO}_3\text{Na}$, 354.20451; found, 354.2042.

Methyl 4-(2-Methylphenyl)-2-(morpholino)-oct-3-enoate 3b. Twenty milligrams (60%). Colorless oil, $R_f = 0.40$ (EtOAc/cyclohexane 30:70). Mixture of 2 diastereomers (58:42). ^1H NMR (300 MHz, CDCl_3): δ 7.22–7.12 (m, 3H), 6.93 (d, $J = 6.9$ Hz, 0.4H), 6.92 (d, $J = 6.6$ Hz, 0.6H), 5.58 (d, $J = 9.6$ Hz, 0.4H), 5.56 (d, $J = 10$ Hz, 0.6H), 3.73–3.68 (m, 4H), 3.71 (s, 3×0.4 H), 3.68 (s, 3×0.6 H), 3.28 (d, $J = 9.6$ Hz, 0.4H), 3.23 (d, $J = 9.9$ Hz, 0.6H), 2.56–2.47 (m, 2H), 2.33–2.23 (m, 4H), 2.23 (s, 3×0.4), 2.15 (s, 3×0.6 H), 1.43–1.29 (m, 4H), 0.88 (t, $J = 7.0$ Hz, 3×0.6 H), 0.86 (t, $J = 7.1$ Hz, 3×0.4). ^{13}C NMR (75 MHz, CDCl_3): δ 171.7, 171.6, 148.6, 148.6, 139.4, 139.0, 135.5, 134.1, 130.0, 129.5, 128.0, 127.1, 127.0, 125.2, 125.1, 121.2, 120.8, 68.4, 68.3, 66.7, 51.7, 51.7, 51.1, 51.05, 38.6, 38.2, 29.6, 29.4, 22.4, 22.2, 19.2, 18.9, 13.8. HRMS (ESI⁺): m/z ($M + \text{Na}$)⁺ calcd for $\text{C}_{20}\text{H}_{29}\text{NO}_3\text{Na}$, 354.20451; found, 354.2047.

Methyl 4-(Pyridin-3-yl)-2-(morpholino)-oct-3-enoate 3c. Thirty seven milligrams (82%). Colorless oil, $R_f = 0.15$ (EtOAc/cyclohexane 40:60). ^1H NMR (300 MHz, CDCl_3): δ 8.54 (d, $J = 3.6$ Hz, 1H), 8.50 (s, 1H), 7.49 (dt, $J = 1.9, 7.8$ Hz, 1H), 7.30 (dd, $J = 4.9, 7.5$ Hz, 1H), 5.65 (d, 1H, $J = 10$ Hz), 3.72 (s, 3H), 3.68 (t, $J = 4.6$ Hz, 4H), 3.42 (d, $J = 10$ Hz, 1H), 2.49 (dt, $J = 4.9, 9.5$ Hz, 2H), 2.41–2.26 (m, 4H), 1.36–1.22 (m, 4H), 0.85 (t, $J = 7.0$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 171.4, 149.0, 148.5, 145.2, 135.7, 135.5, 123.1, 122.7, 67.7, 66.7, 52.0, 50.8, 39.0, 29.6, 22.0, 13.7. HRMS (ESI⁺): m/z ($M + \text{H}$)⁺ calcd for $\text{C}_{18}\text{H}_{27}\text{N}_2\text{O}_3$, 319.20162; found, 319.2017.

Methyl 2-Dibenzylamino-4-(4-methylphenyl)-oct-3-enoate 3d. Fifty three milligrams (86%). Colorless oil, $R_f = 0.25$ (EtOAc/cyclohexane 1:99). ^1H NMR (400 MHz, CDCl_3): δ 7.19–7.16 (m, 10H), 7.0 (s, 4H), 5.69 (d, $J = 9.8$ Hz, 1H), 4.07 (d, $J = 9.8$ Hz, 1H), 3.69 (s, 3H), 3.66 (s, 4H), 2.45–2.40 (m, 2H), 2.33 (s, 3H), 1.31–1.28 (m, 4H), 0.86 (t, $J = 7.0$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 173.4, 147.6, 139.6, 136.9, 136.4, 128.7, 128.0, 127.9, 126.6, 120.1, 60.6, 54.9, 51.4, 39.3, 30.1, 22.2, 21.1, 13.9. HRMS (ESI⁺): m/z ($M + \text{H}$)⁺ calcd for $\text{C}_{30}\text{H}_{36}\text{NO}_2$, 442.2746; found, 442.2742.

Methyl 4-(4-Nitrophenyl)-2-(pyridin-4-yl)piperazino-oct-3-enoate 3e. Fifty milligrams (82%). Colorless oil, $R_f = 0.25$ (EtOAc/cyclohexane 20:80). ^1H NMR (300 MHz, CDCl_3): δ 8.21 (d, $J = 8.7$ Hz, 2H), 8.17–8.15 (m, 1H), 7.49–7.42 (m, 1H), 7.36 (d, $J = 8.7$ Hz, 2H), 6.65–6.58 (m, 2H), 5.72 (d, $J = 10.0$ Hz, 1H), 3.75 (s, 3H), 3.56–3.49 (m, 4H), 3.47 (d, $J = 10.0$ Hz, 1H), 2.64–2.57 (m, 2H), 2.47–2.40 (m, 4H), 1.35–1.25 (m, 4H), 0.87 (t, $J = 6.6$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 171.4, 159.2, 147.9, 147.1, 146.6, 137.5, 129.2, 123.5, 122.9, 113.4, 107.0, 67.6, 52.1, 50.3, 45.1, 38.9, 29.7, 22.1, 13.8. HRMS (ESI⁺): m/z ($M + \text{H}$)⁺ calcd for $\text{C}_{24}\text{H}_{31}\text{N}_4\text{O}_4$, 439.23453; found, 439.2342.

Methyl 4-(4-Methoxyphenyl)-2-[4-(1,1-dimethylethoxy)carbonyl]piperazino-oct-3-enoate 3f. Fifty six milligrams (89%). Colorless oil, $R_f = 0.15$ (EtOAc/cyclohexane 10:90). ^1H NMR (300 MHz, CDCl_3): δ 7.08 (d, $J = 8.7$ Hz, 2H), 6.87 (d, $J = 8.7$ Hz, 2H), 5.49 (d, $J = 10.0$ Hz,

1H), 3.81 (s, 3H), 3.72 (s, 3H), 3.56 (d, $J = 9.9$ Hz, 1H), 3.40 (t, $J = 4.5$ Hz, 4H), 2.49–2.39 (m, 2H), 2.39–2.29 (m, 2H), 2.29–2.19 (m, 2H), 1.42 (s, 9H), 1.34–1.21 (m, 4H), 0.84 (t, $J = 7.0$ Hz, 3H). ^{13}C NMR (75 MHz, CDCl_3): δ 172.1, 158.7, 154.6, 148.5, 132.2, 129.3, 120.5, 113.5, 79.6, 67.6, 55.2, 51.9, 50.3, 43.0 (br), 39.4, 29.8, 28.4, 22.1, 13.8. HRMS (ESI⁺): m/z ($M + \text{H}$)⁺ calcd for $\text{C}_{25}\text{H}_{39}\text{N}_2\text{O}_5$, 447.2859; found, 447.2858.

Methyl 2-(Morpholino)-4-(4-methoxyphenyl)-5-(trimethylsilyl)pent-3-enoate 3g. Forty two milligrams (80%). Colorless oil, $R_f = 0.39$ (EtOAc/cyclohexane 10:90). ^1H NMR (300 MHz, CDCl_3): δ 7.17 (d, $J = 8.7$ Hz, 2H), 6.86 (d, $J = 8.8$ Hz, 2H), 5.29 (d, $J = 10.1$ Hz, 1H), 3.82 (s, 3H), 3.74 (s, 3H), 3.70–3.67 (m, 4H), 3.62 (d, $J = 10.1$ Hz, 1H), 2.55–2.45 (m, 2H), 2.33–2.23 (m, 2H), 1.91 (s, 2H), –0.17 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3): δ 172.2, 158.8, 146.2, 133.3, 129.6, 118.1, 113.4, 68.0, 66.9, 55.2, 51.8, 50.9, 31.0, –1.5. HRMS (ESI⁺): m/z ($M + \text{Na}$)⁺ calcd for $\text{C}_{20}\text{H}_{31}\text{NO}_4\text{SiNa}$, 400.19201; found, 400.1913.

Methyl 4-(4-Methylphenyl)-2-(morpholino)-4-phenyl-but-3-enoate 3h. Thirty nine milligrams (80%). Colorless oil, $R_f = 0.40$ (EtOAc/cyclohexane 10:90). ^1H NMR (300 MHz, CDCl_3): δ 7.30–7.25 (m, 5H), 7.21 (d, $J = 7.8$ Hz, 2H), 7.10 (d, $J = 7.9$ Hz, 2H), 6.15 (d, $J = 10.1$ Hz, 1H), 3.77–3.72 (m, 5H), 3.76 (s, 3H), 2.65–2.58 (m, 2H), 2.44–2.38 (m, 2H), 2.40 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 171.4, 148.0, 141.5, 137.5, 135.7, 129.7, 129.0, 128.2, 128.0, 127.5, 122.2, 68.3, 66.8, 52.1, 51.1, 21.3. HRMS (ESI⁺): m/z ($M + \text{Na}$)⁺ calcd for $\text{C}_{22}\text{H}_{25}\text{NO}_3\text{Na}$, 374.17321; found, 374.1736.

Methyl 2-Dibenzylamino-4-(4-nitrophenyl)-4-phenyl-but-3-enoate 3i. Fifty four milligrams (78%). Colorless oil, $R_f = 0.35$ (EtOAc/cyclohexane 7:93). ^1H NMR (400 MHz, CDCl_3): δ 8.03 (d, $J = 8.7$ Hz, 2H), 7.35–7.17 (m, 17H), 6.43 (d, $J = 9.8$ Hz, 1H), 4.10 (d, $J = 9.8$ Hz, 1H), 3.86 (d, $J = 13.7$ Hz, 2H), 3.83 (s, 3H), 3.72 (d, $J = 13.7$ Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3): δ 172.2, 147.0, 145.6, 144.8, 140.7, 139.0, 130.4, 128.7, 128.4, 128.3, 128.2, 127.6, 127.0, 124.6, 123.4, 60.4, 55.0, 51.8. HRMS (ESI⁺): m/z ($M + \text{Na}$)⁺ calcd for $\text{C}_{31}\text{H}_{28}\text{N}_2\text{O}_4\text{Na}$, 515.19468; found, 515.1948.

Oxidation of Boronate 2a. Sodium perborate monohydrate (45 mg, 0.45 mmol) was added to a stirred solution of ester 2a (50 mg, 0.14 mmol) in THF (2 mL) and water (2 mL) at room temperature. The reaction mixture was stirred during 12 h and then diluted with water. The aqueous layer was extracted with Et_2O (2×5 mL). The combined organic extracts were dried over MgSO_4 and evaporated under vacuum. The resulting residue was purified by column chromatography (230–400 mesh silica gel, EtOAc/cyclohexane, 1:9 to 1:2) to afford γ -keto amino ester 4 (26 mg) in 74% yield as a colorless oil.

Methyl 2-(Morpholino)-4-oxo-octanoate 4. ^1H NMR (400 MHz, CDCl_3): δ 3.77–3.73 (m, 1H), 3.67 (s, 3H), 3.67–3.61 (m, 4H), 2.99 (dd, $J = 17.0, 9.2$ Hz, 1H), 2.75–2.64 (m, 2H), 2.56–2.47 (m, 2H), 0.86 (t, $J = 7.4$ Hz, 2H), 1.49 (quint, $J = 7.4$ Hz, 2H), 1.24 (hex, $J = 7.4$ Hz, 2H), 0.84 (t, $J = 7.3$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 207.3, 169.8, 65.9, 61.9, 50.7, 49.2, 41.8, 40.6, 24.7, 21.25, 12.8. HRMS (ESI⁺): m/z ($M + \text{Na}$)⁺ calcd for $\text{C}_{13}\text{H}_{23}\text{NO}_4\text{Na}$, 280.1525; found, 280.1523.

Azidation of Boronate 2a. Sodium azide (12 mg, 0.18 mmol) and copper sulfate (15 mg, 0.095 mmol) were added to a stirred solution of

boronic ester **2a** (56 mg, 0.15 mmol) in MeOH (2 mL) at room temperature. The reaction mixture was stirred during 24 h and then diluted with water. The aqueous layer was extracted with CH₂Cl₂ (2 × 5 mL). The combined organic extracts were dried over MgSO₄ and evaporated under vacuum. The resulting residue was purified by column chromatography (230–400 mesh silica gel, EtOAc/cyclohexane, 1:9 to 1:4) to afford γ -azido amino ester **5** (30 mg) in 71% yield as a colorless oil.

Methyl 2-(Morpholino)-4-azido-oct-3-enoate 5. ¹H NMR (400 MHz, CDCl₃): δ 4.74 (d, *J* = 9.5 Hz, 1H), 3.95 (d, *J* = 9.5 Hz, 1H), 3.67 (t, *J* = 4.6 Hz, 4H), 3.66 (s, 3H), 2.56–2.49 (m, 2H), 2.45–2.38 (m, 2H), 2.26 (t, *J* = 7.5 Hz, 2H), 1.47 (quint, *J* = 7.5 Hz, 2H), 1.32 (hex, *J* = 7.5 Hz, 2H), 0.87 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 171.3, 141.2, 109.2, 66.8, 65.35, 52.0, 50.9, 32.2, 29.4, 21.9, 13.7. HRMS (ESI+): *m/z* (M-N₂ + Na)⁺ calcd for C₁₃H₂₂N₂O₃Na, 277.1528; found, 277.1530.

One-Pot Access to Triazole 6. Sodium azide (9 mg, 0.13 mmol) and copper sulfate (11 mg, 0.07 mmol) were added to a stirred solution of ester **2a** (40 mg, 0.11 mmol) in MeOH (2 mL) at room temperature. The reaction mixture was stirred during 24 h. Sodium ascorbate (11 mg, 0.05 mmol) and phenylacetylene (12 mg, 0.12 mmol) were added, and the reaction mixture was stirred for 24 h and then diluted with water. The aqueous layer was extracted with CH₂Cl₂ (2 × 5 mL). The combined organic extracts were dried over MgSO₄ and evaporated under vacuum. The resulting residue was purified by column chromatography (230–400 mesh silica gel, EtOAc/cyclohexane, 1:9 to 1:2) to afford γ -triazolyl amino ester **6** (15 mg) in 36% yield (two steps) as a colorless oil.

Methyl 2-(Morpholino)-4-(4-phenyl-1H-1,2,3-triazol-1-yl)-oct-3-enoate 6. ¹H NMR (400 MHz, CDCl₃): δ 8.01 (s, 1H), 7.80 (d, *J* = 7.1 Hz, 2H), 7.39 (t, *J* = 7.3 Hz, 2H), 7.29 (d, *J* = 7.4 Hz, 1H), 5.71 (d, *J* = 9.4 Hz, 1H), 3.75–3.70 (m, 1H), 3.69 (s, 3H), 3.65 (t, *J* = 4.4 Hz, 4H), 2.63 (t, *J* = 7.3 Hz, 2H), 2.70–2.43 (m, 4H), 1.37–1.26 (m, 4H), 0.83 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 169.9, 147.3, 141.9, 130.1, 129.0, 128.4, 125.7, 120.7, 66.6, 65.4, 52.0, 50.6, 35.9, 28.8, 21.9, 13.7. HRMS (ESI+): *m/z* (M + H)⁺ calcd for C₂₁H₂₈N₄O₃Na, 407.2059; found, 407.2054.

■ ASSOCIATED CONTENT

Ⓢ Supporting Information

¹H, ¹³C, and ¹¹B NMR spectra of compounds **2a–i**. NOESY NMR spectrum of compound **2b**. ¹H and ¹³C spectra of compounds **3–6**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Authors

*E-mail: esmvee@iict.res.in (G.V.M.S.).

*E-mail: bertrand.carboni@univ-rennes1.fr (B.C.).

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This research has been performed as part of the Indo-French “Joint Laboratory for Sustainable Chemistry at Interfaces”. We thank CNRS, CSIR, and University of Rennes 1 for support of this research. T.S. thanks CSIR for financial assistance.

■ REFERENCES

- (1) *Boronic acids: Preparation, Applications in Organic Synthesis and Medicine*, 2nd ed.; Hall, D. G., Ed.; Wiley VCH: Weinheim, Germany, 2011.
- (2) (a) Ishiyama, T.; Matsuda, N.; Miyaura, N.; Suzuki, A. *J. Am. Chem. Soc.* **1993**, *115*, 11018. (b) Ishiyama, T.; Matsuda, N.; Murata, M.; Ozawa, F.; Suzuki, A.; Miyaura, N. *Organometallics* **1996**, *15*, 713.
- (3) (a) Ishiyama, T.; Yamamoto, M.; Miyaura, N. *Chem. Lett.* **1996**, *25*, 1117. (b) Brown, S. D.; Armstrong, R. W. *J. Org. Chem.* **1997**, *62*, 7076.

(c) Yavari, K.; Moussa, S.; Ben Hassine, B.; Retailleau, P.; Voiturez, A.; Marinetti, A. *Angew. Chem., Int. Ed.* **2012**, *51*, 6748. (d) Mace, A.; Tripotteau, F.; Zhao, Q.; Gayon, E.; Vrancken, E.; Campagne, J.-M.; Carboni, B. *Org. Lett.* **2013**, *15*, 906.

(4) For intramolecular versions, see: (a) Carson, M. W.; Giese, M. W.; Coghlan, M. J. *Org. Lett.* **2008**, *10*, 2701. (b) Yoshida, H.; Asatsu, Y.; Mimura, Y.; Ito, Y.; Oshita, J.; Takaki, K. *Angew. Chem., Int. Ed.* **2011**, *50*, 9676.

(5) Iwadate, N.; Sugimone, M. *J. Am. Chem. Soc.* **2010**, *132*, 2548.

(6) Baldoli, C.; Bossi, A.; Giannini, C.; Licandro, E.; Maiorana, S.; Perdicchia, D.; Schiavo, M. *Synlett* **2005**, 1137.

(7) (a) Shimizu, M.; Tomioka, Y.; Nagao, I.; Kadowaki, T.; Hiyama, T. *Chem.—Asian J.* **2012**, *7*, 1644 and references therein. (b) Lin, Q. X.; Ho, T. L. *Tetrahedron* **2013**, *69*, 2996.

(8) Yamamoto, Y. *Adv. Synth. Catal.* **2010**, *352*, 478.

(9) Mazuela, J.; Norrby, P. O.; Andersson, P. G.; Pàmies, O.; Diéguez, M. *J. Am. Chem. Soc.* **2011**, *133*, 13634.

(10) Ramirez, J.; Fernandez, E. *Synthesis* **2005**, 1698.

(11) Singleton, D. A.; Redman, A. M. *Tetrahedron Lett.* **1994**, *35*, 509.

(12) For recent reviews on the Petasis three-component coupling reaction, see: (a) Candeias, N. R.; Montalbano, F.; Cal, P. M. S. D.; Gois, P. M. P. *Chem. Rev.* **2010**, *110*, 6169. (b) Batey, R. A. In *Boronic Acids: Preparation and Applications in Organic Synthesis, Medicine and Materials*, 2nd ed.; Hall, D. G., Ed.; Wiley-VCH: Weinheim, Germany, 2011; pp 427–477. (c) Carboni, B.; Berrée, F. In *Science of Synthesis: Multicomponent Reactions*; Müller, T. J. G., Ed.; Thieme: New York, 2013; Vol 5, pp 219–259.

(13) For recent selected examples, see: (a) Norsikian, S.; Soule, J. F.; Cannillo, A.; Guillot, R.; Tran Huu Dau, M. E.; Beau, J. M. *Org. Lett.* **2012**, *14*, 544. (b) Le Quement, S. T.; Flagstad, T.; Mikkelsen, R. J.; Hansen, M. R.; Givskov, M. C.; Nielsen, T. E. *Org. Lett.* **2012**, *14*, 640. (c) Li, Y.; Xu, M. H. *Org. Lett.* **2012**, *14*, 2062. (d) Han, W. Y.; Wu, Z. J.; Zhang, X. M.; Yuan, W. C. *Org. Lett.* **2012**, *14*, 976. (e) Mizuta, S.; Onomura, O. *RSC Adv.* **2012**, *2*, 2266. (f) Ascic, E.; Le Quement, S. T.; Ishoey, M.; Daugaard, M.; Nielsen, T. E. *ACS Comb. Sci.* **2012**, *14*, 253. (g) Frauenlob, R.; Garcia, C.; Bradshaw, G. A.; Burke, H. M.; Bergin, E. J. *Org. Chem.* **2012**, *77*, 4445. (h) Chrzanowska, M.; Grajewska, A.; Meissner, Z.; Rozwadowska, M.; Wiatrowska, I. *Tetrahedron* **2012**, *68*, 3092. (i) Ghosal, P.; Shaw, A. K. *J. Org. Chem.* **2012**, *77*, 7627. (j) Cannillo, A.; Norsikian, S.; Retailleau, P.; Dau Tran Huu, M. E.; Iorga, B. I.; Beau, J. M. *Chem.—Eur. J.* **2013**, *19*, 9127. (k) Han, W. Y.; Zuo, J.; Zhan, X. M.; Yuan, W. C. *Tetrahedron* **2013**, *69*, 537.

(14) (a) Sharma, G. V. M.; Reddy, N. Y.; Ravi, R.; Sreenivas, B.; Sridhar, G.; Chatterjee, D.; Kunwar, A. C.; Hofmann, H. J. *Org. Biomol. Chem.* **2012**, *10*, 9191. (b) Sharma, G. V. M.; Kodeti, S. R.; Dutta, S. K.; Velaparthy, S.; Narsimulu, K.; Anjaiah, G.; Basha, S. J.; Kunwar, A. C. *Chem.—Eur. J.* **2012**, *18*, 16046. (c) Sharma, G. V. M.; Yadav, T. A.; Choudhary, M.; Kunwar, A. C. *J. Org. Chem.* **2012**, *77*, 6834. (d) Sharma, G. V. M.; Sridhar, T.; Reddy, P. P.; Kunwar, A. C. *Eur. J. Org. Chem.* **2013**, 3543.

(15) (a) Berrée, F.; Gernigon, N.; Hercouet, A.; Lin, C. H.; Carboni, B. *Eur. J. Org. Chem.* **2009**, 329. (b) Tripotteau, F.; Verdelet, T.; Hercouet, A.; Carreaux, F.; Carboni, B. *Chem.—Eur. J.* **2011**, *17*, 13670. (c) Vovard-Le Bray, C.; Klein, H.; Dixneuf, P. H.; Macé, A.; Berrée, F.; Carboni, B.; Derien, S. *Adv. Synth. Catal.* **2012**, *354*, 1919.

(16) (a) Touchet, S.; Carreaux, F.; Carboni, B.; Bouillon, A.; Boucher, J.-L. *Chem. Soc. Rev.* **2011**, *40*, 3895. (b) Smoum, R.; Rubinstein, A.; Dembitsky, V. M.; Srebnik, M. *Chem. Rev.* **2012**, *112*, 4156.

(17) Jourdan, H.; Gouhier, G.; Van Hijfte, L.; Angibaud, P.; Piettre, S. R. *Tetrahedron Lett.* **2005**, *46*, 8027.

(18) For recent reviews, see: (a) Valente, C.; Organ, M. G. In *Boronic Acids: Preparation, Applications in Organic Synthesis and Medicine*, 2nd ed.; Hall, D. G., Ed.; Wiley VCH: Weinheim, Germany, 2011; pp 213–262. (b) Carboni, B.; Carreaux, F. In *Cross-Coupling and Heck-Type Reactions*; Larhed, M.; Wolfe, J. P.; Molander, G., Eds.; Georg Thieme: Stuttgart, Germany, 2012; pp 265–322. (c) Lennox, A. J.; Lloyd-Jones, G. C. *Angew. Chem., Int. Ed.* **2013**, *52*, 7362. (d) Lennox, A. J.; Lloyd-Jones, G. C. *Chem. Soc. Rev.* **2014**, *43*, 412–443.

(19) Tao, C. Z.; Cui, X.; Li, J.; Liu, A. X.; Liu, L.; Guo, Q. X. *Tetrahedron Lett.* **2007**, *48*, 3525.

(20) For some recent examples of this one-pot process, see: (a) Akula, H. K.; Lakshman, M. K. *J. Org. Chem.* **2012**, *77*, 8896. (b) Happ, B.; Schaefer, J.; Friebe, C.; Goerls, H.; Winter, A.; Hager, M. D.; Popp, J.; Dietzek, B.; Schubert, U. S. *Synthesis* **2012**, 2287. (c) Clouser, C.; Chauhan, J.; Bess, M. A.; Oploo, J. L.; Zhou, D.; Dimick-Gray, S.; Mansky, L. M.; Patterson, S. E. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 6642. (d) Mukherjee, N.; Ahammed, S.; Bhadra, S.; Ranu, B. C. *Green Chem.* **2013**, *15*, 389.

(21) Because of its explosiveness and toxicity, diazomethane was directly generated in diethyl ether and used without further purification after simple decantation, see: Arndt, F. *Org. Synth.* **1935**, *15*, 3; *Org. Synth.* **1943**, *II*, 165.